Gene Activity List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Gene Compound Experiment Study Pathway Assay Report Bug Request Feature
Gene Activity List
You are on Page 53 of 1714:
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63
Gene Compound Assay Inh Ic50 Ki View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit L-744832 Calcium Channel Type L, Benzothiazepine 81% 3.568uM 3.172uM View
calcium channel, voltage-dependent, beta 1 subunit L-744832 Calcium Channel Type L, Benzothiazepine 81% 3.568uM 3.172uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit L-744832 Calcium Channel Type L, Benzothiazepine 81% 3.568uM 3.172uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit L-744832 Calcium Channel Type L, Benzothiazepine 81% 3.568uM 3.172uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 L-744832 Calcium Channel Type L, Benzothiazepine 81% 3.568uM 3.172uM View
5-hydroxytryptamine (serotonin) receptor 2A QUINACRINE Serotonin 5-HT2A 81% 2.663uM .761uM View
acetylcholinesterase (YT blood group) QUINACRINE Acetylcholinesterase 81% 2.667uM NoneNone View
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase QUINACRINE Acetylcholinesterase 81% 2.667uM NoneNone View
acetylcholinesterase QUINACRINE Acetylcholinesterase 81% 2.667uM NoneNone View
adrenergic receptor, alpha 2b KETOTIFEN Adrenergic alpha2B 81% .71uM .324uM View
arginine vasopressin receptor 1A RITONAVIR Vasopressin V1A 81% 12.416uM 4.981uM View
mu-opioid receptor MOR CYPROTERONE ACETATE Opiate mu 81% 2.183uM .886uM View
5-hydroxytryptamine (serotonin) receptor 1B OLANZAPINE Serotonin 5-HT1B 81% .707uM .433uM View
calcium channel, voltage-dependent, gamma subunit 8 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 7 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 6 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 5 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 4 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 3 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 2 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, gamma subunit 1 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, beta 4 subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, beta 3 subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, beta 2 subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
sodium channel associated protein 2 PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type III, beta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type I, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type IX, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type VII, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
amiloride-sensitive cation channel 5, intestinal PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type III, beta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type XI, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type I, beta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type 10, alpha polypeptide PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type IV, alpha polypeptide PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type V, alpha polypeptide PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type II, beta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1 alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1 gamma PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1 beta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type XI, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1, gamma PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1, delta PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, nonvoltage-gated 1 alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type X, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type IX, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage gated, type VIII, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
sodium channel, voltage-gated, type VII, alpha PIPAMAZINE Sodium Channel, Site 2 80% 2.686uM 2.451uM View
prostaglandin-endoperoxide synthase 2 KETOPROFEN Cyclooxygenase COX-2 80% .785uM NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) KETOPROFEN Cyclooxygenase COX-2 80% .785uM NoneNone View
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) MICONAZOLE Protein Tyrosine Kinase, HER2 Receptor 80% 27.43uM NoneNone View
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) MICONAZOLE Protein Tyrosine Kinase, HER2 Receptor 80% 27.43uM NoneNone View
epidermal growth factor receptor CIGLITAZONE Protein Tyrosine Kinase, EGF Receptor 80% 4.655uM NoneNone View
matrix metallopeptidase 9 BUDESONIDE Protease, Matrix Metalloprotease-9 (MMP-9) 80% 1.989uM NoneNone View
matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) BUDESONIDE Protease, Matrix Metalloprotease-9 (MMP-9) 80% 1.989uM NoneNone View
Protein-tyrosine kinase, Fyn AURANOFIN Protein Tyrosine Kinase, Fyn 80% 1.197uM NoneNone View
calcium channel, voltage-dependent, beta 1 subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 8 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 7 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 6 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 5 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 4 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 3 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 2 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, gamma subunit 1 DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, beta 4 subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, beta 3 subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit FLUNARIZINE Calcium Channel Type L, Benzothiazepine 83% 1.12uM .995uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit FLUNARIZINE Calcium Channel Type L, Benzothiazepine 83% 1.12uM .995uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 FLUNARIZINE Calcium Channel Type L, Benzothiazepine 83% 1.12uM .995uM View
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) NIFURSOL CYP450-2C9 Inhibition 83% 7uM NoneNone View
cytochrome P450, family 2, subfamily C, polypeptide 9 NIFURSOL CYP450-2C9 Inhibition 83% 7uM NoneNone View
Cytochrom P450-2C19 monooxygenase TICLOPIDINE CYP450-2C19 Inhibition 83% .6678uM NoneNone View
mitogen activated protein kinase 14 FENBENDAZOLE Protein Serine/Threonine Kinase, p38alpha 83% 3.188uM NoneNone View
mitogen-activated protein kinase 14 FENBENDAZOLE Protein Serine/Threonine Kinase, p38alpha 83% 3.188uM NoneNone View
cholinergic receptor, muscarinic 2 MAPROTILINE Muscarinic M2 83% 1.927uM .685uM View
sodium channel, voltage-gated, type IV, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type III, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type II, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type II, alpha 2 SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type I, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type I, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type IV, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel associated protein 1 SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel associated protein 2 SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type III, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type I, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type IX, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type VII, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
amiloride-sensitive cation channel 5, intestinal SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type III, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type XI, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type I, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type 10, alpha polypeptide SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type IV, alpha polypeptide SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type V, alpha polypeptide SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type II, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1 alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1 gamma SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1 beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type XI, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1, gamma SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1, delta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, nonvoltage-gated 1 alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type X, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type IX, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage gated, type VIII, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type VII, alpha SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
sodium channel, voltage-gated, type IV, beta SPIRADOLINE Sodium Channel, Site 2 83% 3.086uM 2.815uM View
adrenergic receptor, alpha 2a IVERMECTIN Adrenergic alpha2A 83% 5.8398uM 2.1899uM View
adrenergic receptor, alpha 2a QUETIAPINE Adrenergic alpha2A 83% 2.4914uM .9343uM View
cholinergic receptor, muscarinic 4 QUETIAPINE Muscarinic M4 83% 1.5787uM .2202uM View
adrenergic receptor, alpha 2a PROMAZINE Imidazoline I2, Central 83% 1.098uM .732uM View
adrenergic receptor, alpha 2c (Non-specific probe) PROMAZINE Imidazoline I2, Central 83% 1.098uM .732uM View
5-hydroxytryptamine (serotonin) receptor 2A TERCONAZOLE Serotonin 5-HT2A 83% 8.175uM 2.336uM View
prostaglandin-endoperoxide synthase 1 TENOXICAM Cyclooxygenase COX-1 83% 1.14uM NoneNone View
calcium channel, voltage-dependent, L type, alpha 1S subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, alpha 1F subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, beta 1 subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 OXYBUTYNIN Calcium Channel Type L, Phenylalkylamine 81% 2.358uM 2.2925uM View
histamine receptor H 2 ORPHENADRINE Histamine H2 81% 6.961uM 6.845uM View
5-hydroxytryptamine receptor 6 EBASTINE Serotonin 5-HT6 81% 2.1974uM 1.0202uM View
cytochrome P450, family 3, subfamily a, polypeptide 13 AMPRENAVIR CYP450-3A4 Inhibition 81% 1uM NoneNone View
epidermal growth factor receptor CETYLPYRIDINIUM BROMIDE Protein Tyrosine Kinase, EGF Receptor 81% 3.472uM NoneNone View
thromboxane A synthase 1 CETYLPYRIDINIUM BROMIDE Thromboxane Synthetase 81% 6.452uM NoneNone View
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) CETYLPYRIDINIUM BROMIDE Thromboxane Synthetase 81% 6.452uM NoneNone View
tachykinin receptor 2 RALOXIFENE Tachykinin NK2 81% 3.989uM 1.33uM View
Protein-tyrosine kinase, Fyn RALOXIFENE Protein Tyrosine Kinase, Fyn 81% 3.666uM NoneNone View
arachidonate 15-lipoxygenase, second type PROPOFOL Lipoxygenase 15-LO 81% 7.596uM NoneNone View
arachidonate 15-lipoxygenase PROPOFOL Lipoxygenase 15-LO 81% 7.596uM NoneNone View
arachidonate 15-lipoxygenase PROPOFOL Lipoxygenase 15-LO 81% 7.596uM NoneNone View
cholinergic receptor, muscarinic 1 SB-203580 Muscarinic M1 81% 10.666uM 2.569uM View
dopamine receptor D1A BAY 11-7085 Dopamine D1 81% 4.412uM 2.206uM View
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) ASTEMIZOLE Protein Tyrosine Kinase, HER2 Receptor 81% 13.084uM NoneNone View
calcium channel, voltage-dependent, beta 1 subunit NIFEDIPINE Calcium Channel Type L, Benzothiazepine 81% .00867uM .007707uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit NIFEDIPINE Calcium Channel Type L, Benzothiazepine 81% .00867uM .007707uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit NIFEDIPINE Calcium Channel Type L, Benzothiazepine 81% .00867uM .007707uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 NIFEDIPINE Calcium Channel Type L, Benzothiazepine 81% .00867uM .007707uM View
5-hydroxytryptamine (serotonin) receptor 2B DICYCLOMINE Serotonin 5-HT2B 81% 1.301uM .828uM View
sodium channel, voltage-gated, type IV, beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel associated protein 1 TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel associated protein 2 TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type III, beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type I, alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type IX, alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type VII, alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
amiloride-sensitive cation channel 5, intestinal TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type III, beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type XI, alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type I, beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type 10, alpha polypeptide TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type IV, alpha polypeptide TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type V, alpha polypeptide TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type II, beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, nonvoltage-gated 1 alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, nonvoltage-gated 1 gamma TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, nonvoltage-gated 1 beta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, voltage-gated, type XI, alpha TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, nonvoltage-gated 1, gamma TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
sodium channel, nonvoltage-gated 1, delta TETRACAINE Sodium Channel, Site 2 81% 1.7uM 1.551uM View
calcium channel, voltage-dependent, beta 2 subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, alpha 1F subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit DANAZOL Calcium Channel Type L, Benzothiazepine 80% 14.649uM 13.021uM View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 BETA-ESTRADIOL Serotonin Transporter 80% 10.755uM 5.714uM View
cholinergic receptor, muscarinic 1 4-OCTYLPHENOL Muscarinic M1 80% 18.013uM 4.338uM View
calcium channel, voltage-dependent, gamma subunit 2 PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, gamma subunit 1 PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, beta 4 subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, beta 3 subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, beta 2 subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, alpha 1F subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, beta 1 subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit PERHEXILINE Calcium Channel Type L, Phenylalkylamine 80% 1.3499uM 1.3124uM View
cytochrome P450, family 3, subfamily a, polypeptide 13 DILTIAZEM CYP450-3A4 Inhibition 80% 1.8366uM NoneNone View
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 PERHEXILINE Adrenergic, Norepinephrine Transporter 80% 3.2942uM 3.267uM View